(The Mount Sinai Hospital / Mount Sinai School of Medicine) Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy. Ketamine, which has been repurposed as a rapidly acting antidepressant, has emerged as an experimental and potentially promising compound to treat severe depression through a novel drug action mechanism that blocks glutamate receptors.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2nuKel8
No comments:
Post a Comment